[IDDM treatment with an insulin-expressing vector].
Islet transplantation has proven successful at delivering insulin in a regulated manner. However, the scarcities of islet donors are important limitations. The idea of engineering non-beta cell such as hepatocytes, myocytes, to produce insulin emerged at the end of 80's. To attain insulin production similarly to islet beta cell, a number of devices has been performed, including proinsulin processing and regulated secretion of insulin, resulting in functioning beta-cell surrogates to some extent. These attempts will be merged with currently on-going islet-regeneration therapies from multipotent embryonic stem (ES) cells.